海普瑞(09989.HK) 公布,全资子公司天道医药生产的依诺肝素钠注射液(商品名︰Ivenoxin)获得南非健康产品监管局上市许可,适应症主要包括预防术前术后血栓形成;及降低因急性疾病导致活动受限患者的血栓风险等,有效期五年。(de/d)(港股报价延迟最少十五分钟。)
Disclaimer: Investing carries risk. This is not financial advice. The above content should not be regarded as an offer, recommendation, or solicitation on acquiring or disposing of any financial products, any associated discussions, comments, or posts by author or other users should not be considered as such either. It is solely for general information purpose only, which does not consider your own investment objectives, financial situations or needs. TTM assumes no responsibility or warranty for the accuracy and completeness of the information, investors should do their own research and may seek professional advice before investing.